Loading stock data…
SAB Biotherapeutics (SABS)
$3.51-0.07 (-1.96%)
Market ClosedLast close Jul 24
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
SAB Biotherapeutics, Inc. in the Healthcare sector is trading at $3.51 with a market capitalization of $295M. Wall Street consensus targets $11.18 (11 analysts), implying a +218.6% move over the next 12 months. The stock is currently 32% below its 52-week high of $5.15, remaining 5.1% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: MACD remains below its signal line. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +218.6% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 32) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$20.00M↓ | -$15.77M↓ | -$12.68M↓ | -$9.73M↑ | -$10.77M |
| Net Income | -$18.87M↓ | -$16.86M↓ | $45.45M↑ | -$10.11M↓ | -$5.20M |
Peer Comparison
JNJUNHPFE
Fundamentals
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candi...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$294.77M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-0.18%
Volume
Today's trading volume
954,266
Recent News
SAB Biotherapeutics (SABS) and Breakthrough T1D Award Research Grant For SAB-142 Assessment
SAB Biotherapeutics Inc. (NASDAQ:SABS) is one of the 10 best stocks under $10 that could triple. On July 7, SAB Biotherapeutics Inc. (NASDAQ:SABS) and Breakthrough T1D, a leading research and advocacy firm for type 1 diabetes, disclosed that Breakthrough T1D has awarded a research grant to Michael J. Haller, M.D., Chief Pediatric Endocrinologist and Professor […]
Why Is H.C. Wainwright Bullish On SAB Biotherapeutics (SABS) With $10 Price Target?
SAB Biotherapeutics, Inc. (NASDAQ:SABS) ranks among the overlooked penny stocks to buy right now, supported by strong upside potential. Back-to-back bullish analyst calls are pointing to a wide gap between the company’s market value and the opportunity Wall Street sees in its lead diabetes program. On June 24, 2026, Barclays analyst Eliana Merle initiated coverage […]
Barclays Assigns Overweight Rating to SAB Biotherapeutics Inc. (SABS)
SAB Biotherapeutics Inc. (NASDAQ:SABS) is one of the 10 best stocks under $10 offering more than 50% upside. On June 24, Eliana Merle from Barclays initiated coverage of SAB Biotherapeutics Inc. (NASDAQ:SABS) with a target price of $13, and assigned an Overweight rating to the stock. As per Merle’s projections, the stock currently offers a […]
Emergent BioSolutions Inc. (EBS) Gains Attention as ACAM2000 Receives Broader Public Health Authorization
We recently compiled a list of the 8 Best Small Cap Pharma Stocks to Buy Right Now. Emergent BioSolutions Inc. (NYSE:EBS) is one of the best pharmaceutical stocks to invest in. TheFly reported on April 30 that EBS announced that Singapore’s Health Sciences Authority approved an expanded use of ACAM2000, allowing its use in preventing mpox […]
We Think SAB Biotherapeutics (NASDAQ:SABS) Needs To Drive Business Growth Carefully
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, SAB Biotherapeutics...